Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 36.85 1.01% 0.37
DCPH closed up 1.01 percent on Friday, September 13, 2019, on 55 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical DCPH trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Up 3 Days in a Row Strength 0.00%
20 DMA Resistance Bearish 1.01%
Bollinger Band Squeeze Range Contraction 1.01%
Bollinger Band Squeeze Range Contraction 3.63%
Stochastic Reached Oversold Weakness 3.63%
BB Squeeze + Lower Band Touch Range Contraction 3.63%

Older signals for DCPH ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
Medicine Biopharmaceutical Cancer Drugs Immune System Cancer Treatments Antineoplastic Drugs Targeted Therapy Tyrosine Kinase Receptors Glioblastoma Multiforme Protein Kinase Inhibitor Mastocytosis Treatment For Cancer Systemic Mastocytosis
Is DCPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 42.99
52 Week Low 18.55
Average Volume 839,801
200-Day Moving Average 25.6901
50-Day Moving Average 28.748
20-Day Moving Average 36.7425
10-Day Moving Average 36.353
Average True Range 1.9174
ADX 45.99
+DI 31.0794
-DI 13.8653
Chandelier Exit (Long, 3 ATRs ) 33.7278
Chandelier Exit (Short, 3 ATRs ) 39.7922
Upper Bollinger Band 38.4313
Lower Bollinger Band 35.0537
Percent B (%b) 0.53
BandWidth 9.192624
MACD Line 1.9918
MACD Signal Line 2.5852
MACD Histogram -0.5935
Fundamentals Value
Market Cap 1.18 Billion
Num Shares 31.9 Million
EPS -16.03
Price-to-Earnings (P/E) Ratio -2.30
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.73
Resistance 3 (R3) 38.66 37.96 38.41
Resistance 2 (R2) 37.96 37.49 38.00 38.31
Resistance 1 (R1) 37.41 37.19 37.69 37.48 38.20
Pivot Point 36.71 36.71 36.85 36.75 36.71
Support 1 (S1) 36.16 36.24 36.44 36.23 35.50
Support 2 (S2) 35.46 35.94 35.50 35.39
Support 3 (S3) 34.91 35.46 35.29
Support 4 (S4) 34.98